Systemic lupus erythematosus (SLE) is the most common type of lupus, a chronic autoimmune disease where the immune system mistakenly attacks the body's own healthy tissues. The exact cause of SLE isn't fully understood, but it is believed to result from a mix of genetic, environmental, and hormonal factors. Lupus affects multiple organs and systems in the body, and some of the most common symptoms include skin rashes, pain or swelling in the joints, swelling in the feet or around the eyes, and extreme fatigue.
While there is currently no cure for SLE, several treatments are available to help manage symptoms and reduce the risk of serious complications. These include antimalarial medications such as hydroxychloroquine, glucocorticoids like prednisone, biologic therapies such as Benlysta (belimumab), and immunosuppressants like Imuran (azathioprine). Roughly 1.5 million people in the United States are impacted by this incurable autoimmune disease. The U.S. SLE treatment market is valued at $844.14 million, according to a report by Cognitive Market Research.
For comments and feedback: editorial@rttnews.com